Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, discusses steps that should be taken by community physicians when managing a patient with mantle cell lymphoma (MCL). She recommends a thorough hematopathology review to determine the disease stage and subtype, testing for TP53 mutations, and considering clinical trial enrollment. Prof. Vose also mentions trial results indicating that bendamustine plus rituximab for initial therapy, followed by rituximab maintenance, could be a promising regimen for standard-risk patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
